These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15645128

  • 1. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
    Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V.
    Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128
    [Abstract] [Full Text] [Related]

  • 2. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein.
    Bian H, Fournier P, Peeters B, Schirrmacher V.
    Int J Oncol; 2005 Aug; 27(2):377-84. PubMed ID: 16010418
    [Abstract] [Full Text] [Related]

  • 3. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.
    Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V.
    Cancer Gene Ther; 2005 Mar; 12(3):295-303. PubMed ID: 15605075
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R.
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [Abstract] [Full Text] [Related]

  • 7. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.
    Zeng J, Fournier P, Schirrmacher V.
    Int J Oncol; 2004 Aug; 25(2):293-302. PubMed ID: 15254725
    [Abstract] [Full Text] [Related]

  • 8. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V, Haas C, Bonifer R, Ertel C.
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [Abstract] [Full Text] [Related]

  • 9. Construction, expression and immunoassay detection of recombinant plasmid encoding fusion protein of Roman chicken complement C3d and Newcastle disease virus F gene.
    Liu D, Niu ZX.
    Scand J Immunol; 2008 Dec; 68(6):598-606. PubMed ID: 19055698
    [Abstract] [Full Text] [Related]

  • 10. [Rescue of a recombinant Newcastle disease virus expressing the green fluorescent protein].
    Ge JY, Wen ZY, Wang Y, Bao ED, Bu ZG.
    Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):547-51. PubMed ID: 17037052
    [Abstract] [Full Text] [Related]

  • 11. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
    Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A.
    Cancer Res; 2007 Sep 01; 67(17):8285-92. PubMed ID: 17804743
    [Abstract] [Full Text] [Related]

  • 12. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy.
    Zhao H, Janke M, Fournier P, Schirrmacher V.
    Virus Res; 2008 Sep 01; 136(1-2):75-80. PubMed ID: 18538434
    [Abstract] [Full Text] [Related]

  • 13. Agglutination-separation reactions of red blood cells sensitized with Newcastle disease virus: quantities, agglutination characteristics, and serology of altered virus and HN spikes released following neuraminidase reactivation.
    Graves IL.
    Vet Res; 2001 Sep 01; 32(5):475-89. PubMed ID: 11592617
    [Abstract] [Full Text] [Related]

  • 14. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
    Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V.
    Int J Oncol; 2008 Oct 01; 33(4):823-32. PubMed ID: 18813797
    [Abstract] [Full Text] [Related]

  • 15. Immunization with virus-modified tumor cells.
    Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E, Steiner HH.
    Semin Oncol; 1998 Dec 01; 25(6):677-96. PubMed ID: 9865682
    [Abstract] [Full Text] [Related]

  • 16. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.
    Ah-Tye C, Schwartz S, Huberman K, Carlin E, Moscona A.
    Microb Pathog; 1999 Nov 01; 27(5):329-36. PubMed ID: 10545258
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
    Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V.
    Gene Ther; 2007 Dec 01; 14(23):1639-49. PubMed ID: 17914407
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.